Correlation Between *GATA-3*, *Ki67* and p53 Expressions to Histopathology Grading of Breast Cancer in Makassar, Indonesia

Syarif Ibrahim¹, Rosdiana Natzir², Andi Asadul Islam³, Tjakra Manuaba⁴,
A. Benyamin Fachruddin⁵, Burhanuddin Bahar⁶, William Hamdani⁷, Husni Cangara⁸,
Mochammad Hatta^{9,*}

¹Department of Surgery, Wahidin Sudirohusodo General Hospital, Makassar, Indonesia

²Department of Biochemistry, Faculty of Medicine, Hasanuddin University, Makassar, Indonesia

³Department of Surgery, Neuro Surgery Division, Wahidin Sudirohusodo General Hospital/Faculty of Medicine, Hasanuddin University, Makassar, Indonesia

⁴Department of Surgery, Sanglah General Hospital/Faculty of Medicine, Udayana University, Denpasar, Indonesia

⁵Department of Internal Division, Wahidin Sudirohusodo General Hospital/Faculty of medicine, Hasanuddin University, Makassar, Indonesia

⁶Department of Epidemiology Faculty of Public Health, Hasanuddin University, Makassar, Indonesia

⁷Department of Surgery, Wahidin Sudirohusodo General Hospital, Faculty of Medicine, Hasanuddin University, Makassar, Indonesia

⁸Department of Pathology Anatomy, Faculty of Medicine, Hasanuddin University, Makassar, Indonesia

⁹Molecular Biology and Immunology Laboratory, Faculty of Medicine, Hasanuddin University, Makassar, Indonesia

Email address:

syarifibrahim57@gmail.com (S. Ibrahim), Rosdiananatzir@yahoo.com (R. Natzir), Andiasadul@yahoo.com (A. A. Islam), Breastca04@yahoo.com (T. Manuaba), Andifach@yahoo.co.id (A. B. Fachruddin), Ninaisywara14@yahoo.co.id (B. Bahar), Williamhamdani_mks@yahoo.co.id (W. Hamdani), husnincangara@yahoo.com (H. Cangara), Hattaram@indosat.net.id (M. Hatta)

*Corresponding author

To cite this article:

Syarif Ibrahim, Rosdiana Natzir, Andi Asadul Islam, Tjakra Manuaba, A. Benyamin Fachruddin, Burhanuddin Bahar, William Hamdani, Husni Cangara, Mochammad Hatta. Correlation Between *GATA-3*, *Ki67* and p53 Expressions to Histopathology Grading of Breast Cancer in Makassar, Indonesia. *Cancer Research Journal*. Vol. 4, No. 3, 2016, pp. 43-47. doi: 10.11648/j.crj.20160403.11

Received: February 2, 2016; **Accepted:** February 24, 2016; **Published:** April 1, 2016

Abstract: *Background:* During the last two decades, research about *GATA-3*, *Ki-67*, p53 expressions have been done, but it is still a debate on their use in predicting breast cancer patients' prognosis and survival rate. Expressions of *GATA-3* decreased with increasing of histopathology grading of breast cancer and increase with decrease of histopathology grading of breast cancer. The level expression of *Ki-67* has a positive relation with breast cancer histopathology grading. p53 has no correlation with high grade differentiation of breast cancer. p53 is a transcription factor which is activated as a part of cellular stress response that can regulate genes' cellular process, including apoptosis and senescence. *Aim:* To determine correlation between expressions of *GATA 3*, *Ki-67* and p53 with histopathology grading of breast cancer in Makassar, Indonesia. *Methods:* Antibody monoclonal *GATA 3*, *Ki-67* and p53 on the nucleus cell were detected with immunohistochemistry method. The positive and negative expressions of *GATA 3*, *Ki-67* and p53 were assessed using scoring system according to the proportion of positive cell and coloring intensities. *Results:* There is no correlation between the higher positive expression of p53 and higher expression of histopathology grading of breast cancer ($P = 0.089$). While *Ki-67* had positive association with higher grade malignancy ($P = 0.03$). However, there was no association between *GATA-3* expression and histopathology grading. *Conclusion:* In our research we found there is no correlation between higher expression of p53 and low expression of *GATA-3* with higher histopathology grading of breast cancer. High expression of *Ki-67* have significantly statistic analysis with high expression of histopathology grading of mammary cancer.

Keywords: *GATA-3*, p53 and *Ki-67*, Histopathology Grading, Breast Cancer

1. Introduction

Breast cancer is a malignancy that occurs in the breast gland. Breast cancer ranks first of the ten types of cancer in women. It was reported incidence of breast cancer in all over the world increase twice, this is the highest level during the late 30 years. WHO predicted the incidence rate of all cancer were 11 millions and every year the amount of breast cancer increase to 7 millions.

In the United States in 2005 reported the incidence of breast cancer by two hundred eleven thousands two hundred forty (211,240) new cases (ACS, 2006). In 2007 the incidence of breast cancer was reported increase to two hundred forty three thousands (243,000) with sixty two thousands (62,000) among them with Carcinoma In Situ (CIS). Breast cancer incidence has increased every year. Data from the American Cancer Society in 2010, stated that there are two hundred seven thousands ninety (207,090) new cases of breast cancer in women in the USA with the estimated number of deaths about thirty nine thousands eight hundred forty (39,840) cases [1]. This figure makes breast cancer as the second most common cause of death in women after lung cancer.

In Indonesia the incidence of breast cancer reported twenty thousands (20,000) new cases/year, around hundred (100) cases among one hundred thousands (100,000) women. 50% were hospitalized in late stages [2].

In Wahidin Sudirohusodo Hospital in Makassar, Indonesia the incidence of breast cancer in 2007 were 163 new cases and became 189 new cases in 2008. There is increasing cases of late stage of mammary cancer and metastatic stage from 69.9% in the year 2007 became 74.1% in the year of 2008 (Wahidin Sudirohusodo Hospital Information System).

Ki-67 expression as detected by immunohistochemistry is one of the most variable indicators of the proliferative status of cancer cells and is referred to as Ki-67. In 2009 at the St-Gallen breast cancer conference, Ki-67 was recommended as a biomarker for prognosis and sensitivity of cancers to endocrine therapy or chemotherapy [3].

Expression of transcription factor *GATA-3* has been shown to be important for normal breast glandular cell development as well for maintaining the differentiated state of cells [4]. Expression of *GATA-3* was significantly increased in breast cancer. Decreasing of *GATA-3* expressions correlate with increasing tumor histological grade and high patient survival [5].

Expression of *p53* in higher differentiated with high proliferation fraction may indicate greater tumor aggressiveness and high risk of relapse [6]. *p53* is a critical tumor suppressor that maintains the genetic stability in mammals by having multiple roles in cells cycle arrest, apoptosis, senescence and differentiation. Loss of *p53* functions is required for the progression of most cancers. The expression of mutant *p53* is correlated with the poor prognosis. The aim of our study was to investigate the expression of *p53*, *Ki-67* and *GATA-3* in correlation with histopathology grading among 50 nested sampling in pathological anatomy laboratory medical faculty in Makassar.

2. Methods

A total of 50 cases of breast cancer were studied in laboratory of anatomic pathology Wahidin Sudirohusodo general hospital Faculty of Medicine, Hasanuddin University Makassar, Indonesia. The research was performed from October 2015 to November 2015 in women from 27 to 73 years old. Fresh tissue from biopsy or tumorectomy was received in department of pathological anatomy and put in buffered formalin solution.

2.1. Histopathology Grading Characteristic

The histopathology grade was determined in sections stained with haematoxylin eosin according to the criteria established and histological type according to the WHO classification (1981).

2.2. Immunohistochemical Study Determination of Expressions of *Ki-67* and *p53*

Immunohistochemical analyses were determined by the expression levels of *Ki-67* and *p53*. Tissues were fixed in 10% formaldehyde for 24 hours, routinely embedded in paraffin and cut into 5- μ m sections. Sections were adherent to APES coated slides and dried at 60°C for 2 hours [7, 8]. Immunohistochemistry was performed according to the manufacturer's instructions, using Streptavidin-Peroxidase (SP-9000) kit, anti *Ki-67* (ZM0166), *p53* (ZM0408), *C-erb2* (ZM0065), all from Zymed laboratories (San Francisco, CA, USA) with antigen retrieval performed according to the manufacturer's instruction. The slides were scored by counting the number of positive cells regardless of the staining intensity versus the total number of cells and calculating the percentage of positive cells (positive cells/total cells in one field), as previously described, the positivity of several fields were averaged and expressed as the ratio of positive cells per field to total cells per field: <10%, negative, 10% - 20%: weakly positive, 26% - 50%: positive, >50%: strong positive. A cut-off point of 25% was used to distinguish between the categories of low and high proliferative tumors, a value similar to 20% or >20% [9-11].

2.3. Immunohistochemistry Staining Procedures of *GATA-3*

Tissue in paraffin blocks of size 5- μ m was cut and glued on the slide poly-L-lysine and then carried. Immunohistochemical staining was using standard methods Avidin-Biotin peroxidase Complex (ABC). Slide that has not been colored was incubated in 0,1% trypsin solution in citrate buffer pH 6 for 10 minutes in the microwave with temperature 37°C. After that examination followed by standard procedure ABC. *GATA-3* using *GATA-3* monoclonal antibody, at a dilution of 1: 200 [12]. Results were evaluated by immunohistochemical staining using light microscope by 2 pathologists and researchers. The expression of *GATA-3* is the accumulation of *GATA-3* in the cell nucleus detected by immunohistochemical

methods. Expression of GATA-3 positive when there is a brown color in the cell nucleus that is seen with a light microscope. This expression is calculated using a scoring system based on the proportion of positive cells and the intensity of the color. Immunoeexpression GATA-3 is expressed in a semiquantitative estimation of the scoring system percentage. 0: No stained cell nucleus, 1: 1-10% stained, 2: 11-20%, 3: 21-30%, 4: 31-40%, 5: 41-50%, 6: 51-60%, 7: 61-70%, 8: 71-80%, 9: 81-90%, 10: 91-100%. Intensity: 1+: weak intensity, 2+: moderate intensity, 3+: strong intensity. Last score obtained by multiplying the intensity of the presentation and the expression of GATA-3 in the cell nucleus to obtain a range of scores 0-30. Then was grouped again to Score 0-3 declared negative, Score 4-30 tested positive [13].

2.4. Statistical Analysis

All the data collection were recorded and then analyzed by using software SPSS 17.0 to compare score expressions of GATA-3, p53 and Ki-67 to scores of breast cancer histopathology grading. Statistical analysis was using chi-square test. *P*-value less than 0.05 was considered statistically significant.

3. Results

3.1. GATA-3, p53, Ki-67 Protein Expression Patterns in Breast Tissue

Figure 1. Positive expression of immunohistochemistry of GATA-3 (200 x).

Figure 2. Positive expression of immunohistochemistry of Ki-67 (200 x).

Figure 3. Positive expression of immunohistochemistry of p53 (200 x).

Characteristics of Samples, The total sample of 50 studies examined in laboratory of Pathology Anatomy, Faculty of Medicine, Hasanuddin University, Makassar, Indonesia.

Table 1. Characteristic Sampling of the Research

Characteristics		Total (N)	Percentage
Age	≤40 ^{yr}	12	24%
	> 40 ^{yr}	38	76%
Histopathology Grading	Low Differentiated	10	20%
	High Differentiated	40	60%
Protein p53	Negative	23	46%
	Positive	27	54%
Protein Ki-67	Negative	17	34%
	Positive	33	66%
GATA 3	Negative	15	30%
	Positive	35	70%

In table 1 the sample was mostly from more than 40 year patients with a percentage of 76% or 38 out of 50 samples. Low differentiated histopathology grading were 20% (10 cases) while high differentiated were 80% (40 cases). The amount of p53 protein positive expressions were 54% (27 cases) where the negative p53 expression levels were 46% (23 cases).

Ki-67 positive expressions were 66% (33 cases) and negative expressions were 34% (17 cases). GATA-3 positive expressions were 70% (35 cases), where negative expressions were 30% (15 cases).

Table 2. Correlation Between The Expression Of Ki67 and Histopathology Grading of Breast Cancer.

		Histopathology Grading		Total
		Low	High	
Ki-67	Positive	3 6,0%	27 54,0%	30 60,0%
	Negative	7 14,0%	13 26,0%	20 40,0%
Total		10 20,0%	40 80,0%	50 100,0%

Correlation between positive expressions Ki-67 with high differentiated histopathology grading were 54% or 27 cases out of 50 cases. While in low differentiated positive expressions of Ki-67 were found in 3 cases with a percentage of 6%. The negative Ki-67 expressions were found in 13 cases (26%) with high differentiated histopathology grading. While negative

Ki-67 expressions were found in 7 cases (14%) with low differentiated histopathology grading.

Table 3. Correlation Between *p53* Expression and Histopathology Grading of Breast Cancer.

		Histopathology Grading		Total
		Low	High	
p53	Positive	3	24	27
		6,0%	48,0%	54,0%
	Negative	7	16	23
		14,0%	32,0%	46,0%
Total		10	40	50
		20,0%	80,0%	100,0%

Correlation of positive *p53* with high differentiated histopathology grading were 48% (24 cases) while *p53* negative with high differentiated histopathology grading were 32% (16 cases). A positive *p53* expressions were found in 3 cases with low differentiated histopathology grading (6%). The percentage of negative *p53* expressions with low differentiated histopathology grading is 14% (7 cases).

Table 4. Correlation Between *GATA-3* Expression With Histopathology Grading Of Breast Cancer.

		Histopathology Grading		Total
		Low	High	
GATA 3	Positive	7	28	35
		14,0%	56,0%	70,0%
	Negative	3	12	15
		6,0%	24,0%	30,0%
Total		10	40	50
		20,0%	80,0%	100,0%

Positive *GATA-3* expressions were seen in high differentiated histopathology grading with a percentage of 56%, 28 among the 50 cases, while *GATA-3* negative expressions found in high differentiated histopathology grading with a percentage of 24% or 12 cases. *GATA-3* is only visible negative 6% (3 cases) in low differentiated histopathology grading. In low differentiated histopathology grading, we found 7 cases with positive *GATA3* expressions (14%).

3.2. Statistical Analysis

In the statistical test using chi-square test, turned out that *P* value was less than 0.05 (*P* = 0.03). This showed that the higher the expression of Ki-67 the higher differentiated result in histopathology grading.

In the statistical test using chi-square test we found that *P* was greater than 0.05 (*P* = 0.089). This shows that the higher expression of *p53* was not correlated significantly with the

higher histopathology grading in this research.

In the statistical test using chi-square test we found that *P* was greater than 0.05 (*P* = 0.1 is not significant). This showed that the low negative expression of *GATA-3* was not significantly correlated with higher differentiated histopathology grading in this research.

4. Discussion

The mutation of *p53* gene is a common phenomenon in numerous human tumors, leading to the accumulation of nonfunctioning *p53* protein in the cell nucleus, which can be detected by Immunohistochemistry.

In breast cancer, it has been suggested that the over expression of *p53* protein in the nucleus is an indicator of poor prognosis, which must be borne in mind in selecting coadjuvant treatment for each patient [14].

In our study we found a positive *p53* expression in high histologic grading is 48.0% among 50 cases and a negative *p53* expression in 16 cases (32.0%) where in statistical analysis there is no correlation between a high expression of *p53* and higher histologic grading of tumor (*P* = 0.089).

Sirvent, Salvado *et al.* study about IHC analysis of *p53* expression in 153 cases of breast cancer, correlating with histological grade, axillary node status, hormone receptors, cell proliferation fraction and expression of the c-erbB-2 oncoprotein. Of all the breast cancer tissue analyzed, 43.97% were positive *p53*, over expression of this protein show direct statistically significant relationship to histological grade, cell proliferation fraction and c-erbB-2, but had no statistically significant relationship with axillary node status.

Mutation and the over expression of *p53* protein are directly related to histological grade [14].

GATA-3 is a nuclear of *GATA-3* transcriptions regulatory family and is important in directing cell fate. Development and or differentiation in a member of cell types including luminal epithelial cells of mammary gland. *GATA-3* is a member of the *GATA-3* transcription regulatory family and is important in directing cell fate, development, and or differentiation in a number of cell types including luminal epithelial cells of the mammary gland. Although we and others have shown that *GATA-3* levels were generally higher in malignant cells compared with morphologically normal epithelium, within malignant tissue, relatively lower levels of *GATA-3* portended a poorer outcome compared with relatively higher expression. Consistent with the role of *GATA-3* in the development and differentiation of normal mammary epithelium, we further observed that lower levels of *GATA-3* were generally associated with a higher-grade, less differentiated malignancy [4].

In this study, we used a IHC to reassess associations of *GATA-3* expression with Histopathologic grading of 50 samples of breast cancer in Makassar. We found that positive expression of *GATA-3* had amount of 28 samples (28%) among high histopathologic grading of breast cancer. Even though the higher expression positive *GATA-3* seen in high histopathologic grading but there is no statistically

significant correlation between them. Negative (low) expression GATA-3 only had 12 samples among high level of histologic grading (20%) of the result.

Mehra *et al.* found low GATA-3 expression was associated with higher histologic grade ($P < 0.001$), positive nodes ($P = 0.002$), larger tumor size ($P = 0.03$), negative estrogen receptor and progesterone receptor ($P < 0.001$ for both) [5].

Ki-67 protein (also known as MKI67) is a cellular marker for proliferation. This nuclear protein is expressed in proliferating cells during G1 through M phases of the cell cycle, but is not detected in resting cells. The Ki-67 expression as detected by immunohistochemistry is one of the most reliable indicators of the proliferative status of cancer cells and is referred to as Ki-67 henceforward. In 2009, at the St-Gallen breast cancer conference, Ki-67 was recommended as a biomarker for prognosis and sensitivity of cancer cells to endocrine therapy or chemotherapy. In 2011, Ki-67 was regarded as one of the factors influencing molecular subtypes. Ki-67 expression is closely associated with the growth and invasion of breast cancer: Ki-67 positive breast cancers are more active in growth, more aggressive in invasion, and more metastatic [3, 7].

In conclusion, we found there is no correlation between higher expression of p53 and low expression of GATA-3 with higher histopathology grading of breast cancer. High expression of Ki-67 have significantly statistic analysis with high expression of histopathology grading of mammary cancer.

References

- [1] American Cancer Society. 2009-2010. Breast Cancer Facts and Figures.
- [2] Tjindarbumi, D., Mangunkusumo, R. 2002. Cancer In Indonesia, Present and Future. Jpn J Clin Onco. (Suplement 1) S17-S21.
- [3] Li, F. Y., Wu, S. G., Zhou, J., et al. 2014. Prognostic Value of Ki-67 in Breast Cancer Patients with Positive Axillary Lymph Nodes: A Retrospective Cohort Study. Open One. 9: 2.
- [4] Yoon, B. S. N. K., Maresh, B. S. E. L., et al. 2010. Higher Levels of GATA-3 Predict Better Survival in Women with Breast Cancer. Human Pathology. 41: 1794-1801.
- [5] Mehra, R., Varambally, S., et al. 2005. Identification of GATA-3 as a Breast Cancer Prognostic Marker by Global Gene Expression Meta-analysis. Cancer Res. 65: 11259-11264.
- [6] Liu, D. P., Song, H., Xu, Y., et al. 2010. A Common Gain of Function of p53 Cancer Mutants in Inducing Genetic Instability. Oncogene. 29: 949-956.
- [7] Cheang, M. C., Chia, S. K., Voduc, D., Gao, D., Leung, S., et al. 2009. Ki-67 Index, HER2 Status, and Prognosis With Luminal B Breast Cancer. Journal of the National Cancer Institute. 101: 736-750.
- [8] Scholzen, T., Gerdes, J. 2000. The Ki-67 Protein: From the Known and The Unknown. Journal of Cellular Physiology. 182: 311-322.
- [9] Goldhirsch, A., Ingle, J. N., Gelbert, R. D., Thurlimann, B., et al. 2009. Thresholds for Therapies: Highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2009. Annals of Oncology. 20: 1319-1329.
- [10] Nishimura, R., Osaka, T. 2010. Clinical Significance of Ki-67 in Neoadjuvant Chemotherapy for Primary Breast Cancer as a Predictor for Chemo sensitivity and for Prognosis. Department of Breast and Endocrine Surgery, Kumamoto City Hospital, Kumamoto, Japan: Japanese Breast Cancer. 17: 269-275.
- [11] Weisner, G. F., Magener, A. 2009. Ki-67 as a Prognostic Molecular Marker in Routine Clinical use in Breast Cancer Patients. The Breast. 18: 135-141.
- [12] Dydensborg, A. B., Rose, A. A. N., et. al. 2009. GATA-3 Inhibits Breast Cancer Growth and Pulmonary Breast Cancer Metastasis. Oncogene. 28: 2634-2642.
- [13] Albergaria, A., Joana, P., et al. 2009. Expression of Foxa1 and GATA-3 in Breast Cancer. The Prognostic Significance in Hormone Receptor-Negative Tumors.
- [14] Sirvent, J. J., Salvado, M. T., et al. 1995. p53 in Breast Cancer. Its Relation to Histological Grade, Lymph-node Status, Hormon Receptors, Cell-Proliferation fraction (Ki-67) and c-erbB-2. Immunohistochemical study of 153 Cases. Histopathol. 10: 531-539.